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ible and adaptable framework can be applied to any therapeutic area and used to
evaluate any number of varying product profiles. It involves understanding how
stakeholders value asset attributes and how their willingness-to-pay helps quan-
tify each individual attributes’ contribution to a price.
PRM161
A PARADIGM SHIFT IN HEALTH ECONOMIC EVALUATIONS FOR DEVELOPING
COUNTRIES - OPTIMIZATION MODELLING FOR ASSESSING WHICH MIX OF
MALARIA PREVENTION STRATEGIES ACHIEVES A DEFINED PUBLIC HEALTH
TARGET AT THE LOWEST BUDGET
Van Vlaenderen I1, Sauboin C2, Van Bellinghen LA1, Standaert B2
1CHESS, Ternat, Belgium, 2GlaxoSmithKline Vaccines, Wavre, Belgium
Malaria remains one of the leading causes of ill health with the majority of cases
and deaths occurring in young children in Sub-Saharan Africa. Key interventions
currently recommended for preventing childhood malaria include Insecticide
Treated Nets, Indoor Residual Spraying, Intermittent Preventive Treatment in in-
fancy, and Seasonal Malaria Chemoprevention. One-to-one comparisons applied
in cost-effectiveness and budget impact analyses fail to examine the health and
economic impact of multiple interventions implemented simultaneously, and are
therefore unable to evaluate the optimal integration of available malaria preven-
tive interventions and partially efficacious vaccines currently in development.
Moreover, an incremental cost-effectiveness ratio with recommended willingness-
to-pay threshold provides limited guidance in developing countries. OBJECTIVE:
Defining an approach to identify the optimal sequence of introducing different
preventive interventions, achieving progressively increasing public health targets
for malaria control in children 5years old at the lowest budget. METHODS: Our
suggested optimization approach integrates two distinguished models to assess
combinations of interventions. A vector model simulates the impact of varying
coverages of vector control interventions on vector infectiousness capacity and
associated reduction in Entomological Inoculation Rate (EIR) for children. A human
host model applies this reduced EIR to simulate disease incidence at varying cov-
erages of interventions directly acting within humans. These connected models
provide all potential intervention combinations achieving a pre-defined public
health target (e.g. reducing childhood mortality with 50%). Considering malaria
policy evolutions at increasing public health targets, a lower bound is set on inter-
vention coverages at each optimization step. The remaining options are ranked
according to their budget impact considering cost of interventions and disease
management in a health system perspective. CONCLUSIONS: Using the optimiza-
tion process with progressively increasing public health targets provides an indi-
cation on the optimal sequence of introducing interventions at the lowest budget.
Therefore, this approach can support decision-making in prioritization of malaria
preventive interventions.
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OBJECTIVES: The selection of the appropriate comparator plays an important role
within the EBAs for innovative medicines in Germany. According to the law the
appropriate comparator typically has to be identified according to the standards of
evidence-based medicine. If there are several alternatives, the economics have to
be taken into consideration. Our aim was to explore differences in comparators as
suggested by the GBA and the pharmaceutical companies. METHODS: The review
includes EBAs that were started in 2011. The Joint Federal Committee’s (GBA) web-
page was used to obtain the respective company dossiers as well as the IQWiG
(Institute for Quality and Efficiency in Health Care) benefit assessments. The ap-
propriate comparators as stated by the companies and the GBA (according to the
IQWiG assessment) were extracted and compared. RESULTS: Twenty-four EBAs
were started in 2011. In 10 EBAs the pharmaceutical company applied the compar-
ator that was suggested by the GBA within the benefit dossier (Tafamidis Meglu-
min, Telaprevir, Abirateronacetat, Boceprevir, Ipilimumab, Fampridin, Belatacept,
Apixaban, Eribulin, Fingolimod), although in some of those cases data for the sug-
gested comparators e.g. for subgroups where not developed within the phase 3
clinical trials (Abirateronacetat, Fampridin, Fingolimod). In 9 EBAs no agree-
ment was reached (Linagliptin, Pirfenidon, Belimumab, Cannabis Sativa, Reti-
gabin, Aliskiren/Amlodipin, Collagenase, Cabazitaxel, Ticacrelor). For five drugs
no full dossier submissions and/or IQWiG assessments were conducted (Brom-
fenac, Dexmedetomidin, Pitavastatin, Regadenoson, Olmesartan/Amlodipin/
Hydrochlorthiazid). In seven EBAs GBA suggested ‘Best Supportive Care’ (BSC) as
appropriate comparator. In two cases optimized standard therapy was chosen
and in one EBA physiotherapy. CONCLUSIONS:Ongoing EBAs indicate a high level
of disagreement between comparators as suggested by GBA and respective com-
panies. Definition of BSC is different across various diseases and evidence levels for
BSC as appropriate comparator is scarce.
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OBJECTIVES: The expected value of perfect information (EVPI) assesses, at a given
willingness-to-pay threshold, the expected gain in net benefit from further re-
search to decrease uncertainty in a decision. If the EVPI exceeds the cost of obtain-
ing new information then further research is considered valuable. The parameters
for which further research is believed to be most valuable can be assessed by
calculating the expected value of perfect parameter information. The objective of
this analysis was to assess the use of EVPI in economic evaluations and health
technology assessment (HTA) from the perspective of the NHS in the UK.
METHODS: An unrestricted search was performed in MEDLINE for literature that
contained references to EVPI and cost-effectiveness analysis or HTA. The literature
obtained was assessed to establish the extent to which EVPI is used in economic
evaluation and HTA. Guidelines from the National Institute for Health and Clinical
Excellence (NICE) were also checked for references to EVPI. RESULTS:The literature
search indicated that out of 73,795 results for HTA or cost-effectiveness analysis,
only 70 (0.01%) of these also reported EVPI. There were 21 examples of calculating
the EVPI in an economic evaluation from a UK perspective; the earliest was pub-
lished in 2004. The NICE guide to the methods of technology appraisal (2008 update)
states that value-of-information methods can be used within a probabilistic sen-
sitivity analysis (PSA) to assess the contribution of uncertainty from each param-
eter to the overall decision uncertainty. However, the specification for manufac-
turer/sponsor submission of evidence does not explicitly request the EVPI to be
calculated as part of the PSA. CONCLUSION: The EVPI is a measure which can aid
decision makers by quantifying the value of further research in an area, but it is not
widely reported in published economic evaluations.
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In order to ensure that new products entering health care markets are cost-effec-
tive over existing products Health Technology Assessment programs are imple-
mented in health care systems. Whereas HTA agencies can screen out underper-
forming products it is equally important that manufacturers implement
procedures to ensure that no underperforming products are developed and
brought to market in the first place. By analogy, there are standards that companies
need to comply with to ensure that their products are safe; similar standards or
methods to ensure that new products are cost-effective could be developed. Based
on 20 years experience of medical device innovation in industry, academia and
consulting a conceptual model to ensure cost-effective innovation is proposed. The
method divides the value assurance process into 3 Stages: concept generation,
concept validation and market entry strategy. During the concept generation phase
solutions to a critical problem with an unmet clinical need and a related disease
burden are generated and evaluated with the core group of clinicians and multiple
stakeholders according to costs, risks and benefits. The most promising concepts
are iteratively tested and validated according to freedom to operate, safety, effi-
cacy, ease-of-use, invasiveness, procedure success rate and head-to-head compar-
ative cost-effectiveness until a candidate product can be addressed to a target
patient group and practitioners at a profitable price. Finally, markets with the best
clinician community support, largest size, highest attainable prices and lowest
barriers to entry are addressed. This may sound as commonsense, but there are
some important evolutionary principles hidden: 1) downstream market selection
criteria are translated into early upstream tests; 2) multiple concepts are generated
to handle early uncertainty; and 3) iterative tests are performed until a satisfying
concept is selected. This model should ensure a product will pass HTA cost-effec-
tiveness evaluation if eventually exposed to it.
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Models developed in Microsoft EXCEL of increasing complexity are being used as an
integral part of the submission process for new pharmaceutical products and for
technical assessments produced by national agencies. The credibility of the health
economic models utilised depends on their validity. Firstly, in terms of reflecting
the appropriate clinical process using the correct data and assumptions and sec-
ondly, in terms of ensuring a correct functioning of the model based on the rela-
tionships between variables and formulas embedded in the model. In this research,
the authors concentrate on the latter aspect of validating health economic models.
While recognising that models should be validated, there is a paucity of detailed
techniques available in the literature that show researchers and users of health
economic models how to validate them. Hence, we have attempted to develop a
methodological framework that may be helpful to both those reviewing complex
models and to model developers themselves who could incorporate validation
processes while they develop their own models. The authors have reviewed the
literature, looked at other disciplines (e.g. finance) where modelling plays a central
role, investigated different software options in addition to the inbuilt validation
tools in EXCEL. The evolving methodology has been applied to a number of existing
real-life models in order to develop a consistent approach. By applying the devel-
oped methodology, errors have been identified at the design/review stage in a
number of budget impact and cost-effectiveness models of varying degrees of com-
plexity. A consistent approach to validation is a useful tool to test the often highly
complex processes and relationships with thousands of formulas in health eco-
nomic models. It may also encourage modellers to take a more disciplined and
organised approach in the development process and give increased confidence to
end-users that the models they are using can be relied upon.
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